Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Tag Archives: therapeutics
Is Vera Therapeutics Inc (VERA) a Bad Choice in Biotechnology Wednesday? – InvestorsObserver
Posted: March 28, 2024 at 2:39 am
Is Vera Therapeutics Inc (VERA) a Bad Choice in Biotechnology Wednesday? InvestorsObserver
Read the original:
Is Vera Therapeutics Inc (VERA) a Bad Choice in Biotechnology Wednesday? - InvestorsObserver
Posted in Biotechnology
Comments Off on Is Vera Therapeutics Inc (VERA) a Bad Choice in Biotechnology Wednesday? – InvestorsObserver
Is G1 Therapeutics Inc (GTHX) Stock at the Top of the Biotechnology Industry? – InvestorsObserver
Posted: March 28, 2024 at 2:39 am
Is G1 Therapeutics Inc (GTHX) Stock at the Top of the Biotechnology Industry? InvestorsObserver
Original post:
Is G1 Therapeutics Inc (GTHX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Posted in Biotechnology
Comments Off on Is G1 Therapeutics Inc (GTHX) Stock at the Top of the Biotechnology Industry? – InvestorsObserver
Is Lyra Therapeutics Inc (LYRA) Stock at the Top of the Biotechnology Industry? – InvestorsObserver
Posted: March 28, 2024 at 2:39 am
Is Lyra Therapeutics Inc (LYRA) Stock at the Top of the Biotechnology Industry? InvestorsObserver
More here:
Is Lyra Therapeutics Inc (LYRA) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Posted in Biotechnology
Comments Off on Is Lyra Therapeutics Inc (LYRA) Stock at the Top of the Biotechnology Industry? – InvestorsObserver
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
Posted: February 21, 2024 at 2:34 am
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
Follow this link:
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
Posted in Global News Feed
Comments Off on PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
YUHS partners with KURE.AI Therapeutics for cell therapy development – KBR
Posted: January 31, 2024 at 2:34 am
YUHS partners with KURE.AI Therapeutics for cell therapy development KBR
The rest is here:
YUHS partners with KURE.AI Therapeutics for cell therapy development - KBR
Posted in Cell Therapy
Comments Off on YUHS partners with KURE.AI Therapeutics for cell therapy development – KBR
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
Posted: January 14, 2024 at 2:35 am
BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that the first patient has been dosed at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research, New York, as part of the randomized Phase 2 (AMPLIFY-7P) study of ELI-002 7P as an adjuvant monotherapy in KRAS mutated pancreatic ductal adenocarcinoma (“PDAC”).
Excerpt from:
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
Posted in Global News Feed
Comments Off on Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
Posted: January 14, 2024 at 2:35 am
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a fireside chat at the B. Riley Securities Virtual Annual Oncology Investor Conference on Thursday, January 18, 2024 at 1:00 p.m. ET.
Follow this link:
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
Posted in Global News Feed
Comments Off on CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
